AI assistant
ImageneBio, Inc. — Director's Dealing 2021
Mar 26, 2021
34275_dirs_2021-03-25_5f517c04-d6f5-4f89-9320-e843de74faf0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Ikena Oncology, Inc. (IKNA)
CIK: 0001835579
Period of Report: 2021-03-25
Reporting Person: Tessier Maude (Chief Business Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 28792 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $2.94 | 2028-08-08 | Common Stock (44475) | Direct | |
| Stock Option (Right to Buy) | $2.15 | 2028-12-17 | Common Stock (9376) | Direct | |
| Stock Option (Right to Buy) | $4.15 | 2029-03-19 | Common Stock (35792) | Direct | |
| Stock Option (Right to Buy) | $4.51 | 2029-12-05 | Common Stock (37228) | Direct | |
| Stock Option (Right to Buy) | $7.87 | 2031-02-11 | Common Stock (99886) | Direct | |
| Stock Option (Right to Buy) | $7.87 | 2031-03-01 | Common Stock (25917) | Direct |
Footnotes
F1: 25% of this option vested and became exercisable on July 16, 2019, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F2: Represents underlying unexercised stock options that were granted on December 18, 2018. The terms of the original grant provide that 25% of this option vested and became exercisable on July 16, 2019, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F3: 25% of this option vested and became exercisable on March 20, 2020, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F4: Represents underlying unexercised stock options that were granted on December 6, 2019. The terms of the original grant provide that 25% of this option vested and became exercisable on December 6, 2020, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F5: 25% of this option shall vest and become exercisable on February 12, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F6: 25% of this option shall vest and become exercisable on March 1, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.